Clinical trial

Tirzepatide vs Liraglutide in Bone

Recruiting now · Not applicable · 1 countries · Registry ID NCT07094568

Recruiting nowNot applicableObservational

What this study is about

This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age30 Years to 65 Years

SexAll

Healthy volunteersNot accepted

ConditionObesity (Disorder)

Full registry criteria

Inclusion Criteria: * Adults aged between 30 and 65 years * BMI ≥40 kg/m² Exclusion Criteria: * Type 2 Diabetes Mellitus (T2DM) and type 1 Diabetes Mellitus (T1DM) * Chronic kidney disease * Liver failure * Heart failure * Malignancy coexistence * Previous bariatric or gastrointestinal surgery involving intestinal bypass * Uncontrolled hypo/hyperthyroidism * Uncontrolled hypo/hyperparathyroidism * Pregnancy and lactation * Recent fracture (within 2 years) * Rare Metabolic Bone Diseases (e.g., Paget's disease of bone, fibrous dysplasia, osteopetrosis) * Inflammatory arthritis * Medications which can affect bone markers: bone-anabolic agents, antiresorptive agents, antiandrogenic agents, vitamin K antagonists, antipsychotic agents, contraceptives, glucocorticoids (oral), methotrexate, thiazides, aromatase inhibitors etc) * Hemolytic anemia

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Change in serum CTX concentrationBaseline and 3 months after intervention initiation

Evaluation of changes in the bone resorption marker CTX at 3 months after intervention initiation in participants treated with tirzepatide versus liraglutide

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Laiko General Hospital🇬🇷 Athens, Attica, Greece

Open map

Maria Evangelia Ioannis Koloutsou, MD (Medical Doctor)Contact

Email · Call 6986606272

Maria Evangelia Ioannis Koloutsou, MD (Medical Doctor)Contact

Email · Call +306986606272

Maria Evangelia Ioannis Koloutsou, MD (Medical Doctor)Principal Investigator